Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 393

1.

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.

Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U.

Am J Respir Crit Care Med. 2006 Jan 15;173(2):180-7. Epub 2005 Oct 13.

2.

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Iklé D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheum. 2013 Sep;65(9):2441-9. doi: 10.1002/art.38044.

3.

Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report.

Ooka S, Maeda A, Ito H, Omata M, Yamada H, Ozaki S.

Mod Rheumatol. 2009;19(1):80-3. doi: 10.1007/s10165-008-0119-z. Epub 2008 Sep 18.

PMID:
18806927
4.

[Treatment of ANCA-associated vascularitides].

Guillevin L, Pagnoux C.

Presse Med. 2007 May;36(5 Pt 2):922-7. Epub 2007 Apr 3. Review. French.

PMID:
17408912
5.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group.

N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905.

6.

Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.

Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L.

Clin Exp Rheumatol. 2007 Jan-Feb;25(1 Suppl 44):S23-7.

PMID:
17428359
7.

Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide.

Henes JC, Fritz J, Koch S, Klein R, Horger M, Risler T, Kanz L, Koetter I.

Clin Rheumatol. 2007 Oct;26(10):1711-5. Epub 2007 May 15.

PMID:
17502992
9.

Advances in the therapy of Wegener's granulomatosis.

Hellmich B, Lamprecht P, Gross WL.

Curr Opin Rheumatol. 2006 Jan;18(1):25-32. Review.

PMID:
16344616
10.

Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.

Calich AL, Puéchal X, Pugnet G, London J, Terrier B, Charles P, Mouthon L, Guillevin L; French Vasculitis Study Group.

J Autoimmun. 2014 May;50:135-41. doi: 10.1016/j.jaut.2014.03.002. Epub 2014 Apr 2.

PMID:
24703438
11.

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.

Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez-Menéndez M, Ytterberg SR, Fervenza FC, Specks U.

Arthritis Rheum. 2012 Nov;64(11):3770-8. doi: 10.1002/art.34584.

12.
13.

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Ding L, Iklé D, Villareal M, Lim N, Brunetta P, Fervenza FC, Monach PA, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2015 Jun;67(6):1629-36. doi: 10.1002/art.39104.

14.

Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients.

de Menthon M, Cohen P, Pagnoux C, Buchler M, Sibilia J, Détrée F, Gayraud M, Khellaf M, Penalba C, Legallicier B, Mouthon L, Guillevin L.

Clin Exp Rheumatol. 2011 Jan-Feb;29(1 Suppl 64):S63-71. Epub 2011 May 11.

PMID:
21586199
15.

Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D.

Rheumatology (Oxford). 2006 Nov;45(11):1432-6. Epub 2006 Apr 21.

PMID:
16632482
16.

B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.

Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D.

Clin Otolaryngol. 2009 Aug;34(4):328-35. doi: 10.1111/j.1749-4486.2009.01968.x.

PMID:
19673980
17.

Two cases of refractory Wegener's granulomatosis successfully treated with rituximab.

Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M, Morimoto S, Kaneda K, Kobayashi S, Hashimoto H, Takasaki Y.

Intern Med. 2007;46(7):409-14. Epub 2007 Apr 2.

18.

Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's).

Recillas-Gispert C, Serna-Ojeda JC, Flores-Suárez LF.

Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2279-84. doi: 10.1007/s00417-015-3198-5. Epub 2015 Oct 27.

PMID:
26507398
19.

Lower doses of rituximab in remission induction for refractory granulomatosis with polyangiitis.

Wawrzycka-Adamczyk K, Zugaj A, Włudarczyk A, Kosałka J, Sznajd J, Bazan-Socha S, Musiał J.

Przegl Lek. 2014;71(12):663-5.

PMID:
25951692
20.

Supplemental Content

Support Center